SHR-2524
/ Jiangsu Hengrui Pharma
- LARVOL DELTA
Home
Next
Prev
1 to 3
Of
3
Go to page
1
April 29, 2026
A Study of SHR-2524 Plus Bevacizumab in the First-line Treatment of Advanced Hepatocellular Carcinoma
(clinicaltrials.gov)
- P1 | N=36 | Recruiting | Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Not yet recruiting ➔ Recruiting
Enrollment open • Hepatocellular Cancer • Oncology • Solid Tumor
March 18, 2026
A Study of SHR-2524 Plus Bevacizumab in the First-line Treatment of Advanced Hepatocellular Carcinoma
(clinicaltrials.gov)
- P1 | N=36 | Not yet recruiting | Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd.
New P1 trial • Hepatocellular Cancer • Oncology • Solid Tumor
March 12, 2026
Jiangsu Hengrui Pharmaceuticals…announced NMPA clearance to initiate a Phase I clinical trial evaluating SHR-2524 injection in combination with bevacizumab as first-line treatment for advanced hepatocellular carcinoma (HCC)
(flcube.com)
New P1 trial • Hepatocellular Cancer
1 to 3
Of
3
Go to page
1